# Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

> **NCT03793478** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 65 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Quizartinib
- **DRUG:** Fludarabine
- **DRUG:** Cytarabine
- **DRUG:** Intrathecal (IT) triple chemotherapy prophylaxis
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT03793478
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-15
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03793478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03793478, "Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03793478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*